Successful treatment of relapsed/refractory transformed aggressive B-cell lymphoma with polatuzumab vedotin combined with bendamustine and rituximab followed by non-myeloablative related HLA-haploidentical stem cell transplantation
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00277-023-05366-4.pdf
Reference8 articles.
1. Sarkozy C, Maurer MJ, Link BK et al (2019) Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol 37:144–152
2. Lin P, Mansoor A, Bueso-Ramos C et al (2003) Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenstőm macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol 120:246–253
3. Sehn LH, Herrera AF, Flowers CR et al (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol: Off J Am Soc Clin Oncol 38:155–165
4. Terui Y, Rai S, Izutu K et al (2021) A phase 2 study of polatuzumab vedtin+bendamustine+rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci 112:2845–2854
5. Liebers N, Duell J, Fitzgerald D et al (2021) Polatuzumab vedtin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphoma. Blood Adv 13:2707–2716
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3